Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03874052
Recruitment Status : Recruiting
First Posted : March 14, 2019
Last Update Posted : October 30, 2019
Incyte Corporation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Uma Borate, OHSU Knight Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022